What is the definition of Tumefactive Multiple Sclerosis?

Tumefactive multiple sclerosis is characterized by a tumor-like lesion larger than two centimeters and signs and symptoms similar to those of a brain tumor. It is a rare form of multiple sclerosis (MS). Symptoms of tumefactive MS often differ from other MS cases and may include, headaches, changes in thinking, confusion, speech problems, seizures, and weakness. The cause of tumefactive MS is not known. It often develops into the relapsing-remitting form of MS. In other cases there is only one occurrence of the condition. In still others the disease process remains less clear. While there is no cure for tumefactive MS, treatments such as corticosteroids are available to decrease disease activity.

What are the alternative names for Tumefactive Multiple Sclerosis?

  • Diffuse cerebral sclerosis of Schilder
  • Concentric demyelination
  • Balo's concentric sclerosis
  • Marburg variant
  • Balo disease
  • Baló concentric sclerosis
  • Balo's disease
  • Encephalitis periaxialis concentrica

What are the current treatments for Tumefactive Multiple Sclerosis?

To date there have been no controlled treatment studies for tumefactive multiple sclerosis. As a result, treatment decisions are largely based on a doctor's experience and information from single case reports.

In a small number of cases, people with tumefactive multiple sclerosis have minimal to no symptoms. A reasonable approach of care in these cases is to monitor without treatment.

In most cases the size of the lesion and resulting symptoms prompts treatment with corticosteroids. As with other forms of multiple sclerosis, corticosteroids (for example, intravenous methylprednisolone) should be the first line of treatment.  If corticosteroids are not effective, plasma exchange is tried. Another second line treatment that has been tried with some success is Rituximab.

There is no recent research available for this condition. Please check back because thousands of new papers are published every week and we strive to find and display the most recent relevant research as soon as it is available.

Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2/Phase 3
  • Intervention Type: Other, Drug
  • Participants: 60
  • Start Date: September 28, 2020
Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy
Clinical Trial
  • Status: Recruiting
  • Participants: 50
  • Start Date: January 2014
Natural History Study of Alpers Huttenlocher Syndrome